BC Innovations | Aug 29, 2019
Emerging Company Profile

Hesperos: uniting organs on a chip

Hesperos hopes to supplant animal models as the standard preclinical testing ground by designing reconfigurable, multi-organ chips to predict drug efficacy and toxicity early in development. The organ-on-a-chip company spun out of the Tissue Chip...
BC Extra | Apr 19, 2019
Clinical News

Pfizer, Lilly to mull anti-NGF mAb's future after joint safety events spike in long-term readout

With the latest Phase III data for Pfizer and Lilly's tanezumab showing a long-term increase in the incidence of a safety concern that has dogged the anti-NGF mAb, the partners said late Thursday they now...
BC Week In Review | Oct 26, 2018
Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab led to...
BC Extra | Oct 24, 2018
Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data late Tuesday from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab...
BC Extra | Sep 6, 2018
Company News

Management tracks: Rheos, Aileron

Immunometabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Sanjay Keswani as CEO. He was SVP and global head of neuroscience, ophthalmology and rare disease for the Pharma Research and Early Development (pRED) group at Roche...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Extra | Aug 8, 2017
Company News

Depomed plummets on reduced sales guidance

Four weeks after reiterating its 2017 revenue guidance, Depomed Inc. (NASDAQ:DEPO) disappointed investors by lowering its top-line outlook when it reported 2Q17 earnings on Monday after market close. The company lost a third of its...
BC Innovations | Jul 27, 2017
Product R&D

Spheres of influence

AstraZeneca plc and Genentech Inc. have joined forces to test whether a liver spheroid system can improve upon the gold standard for preclinical prediction of hepatotoxicity. The goal is to raise the bar on preventing...
BC Innovations | May 16, 2017
Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Arthritis; pain Cell culture and mouse studies suggest a pyrazolopyridine-based GPR4 inhibitor could help treat arthritis or pain. Chemical synthesis of pyrazolopyridine analogs and testing in a human cell line yielded an oxadiazole-containing compound...
BioCentury | May 9, 2016
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/6 cls Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Leerink Partners Paul Matteis Downgrade Market perform (from outperform) -14% $27.65 Matteis also lowered...
Items per page:
1 - 10 of 423